May 27, 2025

Strategy for Managing Immunotherapy-Induced Parkinsonism in Patients With Multiple Myeloma

The JAK (Janus kinase) inhibitor ruxolitinib may prove to be an effective treatment of parkinsonism arising from immunotherapy for patients with multiple myeloma, according to the results of two case ...

The ASCO Post

May 23, 2025

Early-Phase Trial Shows Activity and Safety of Zongertinib in Previously Treated HER2-Mutant NSCLC

Zongertinib, an investigational oral, HER2-selective, EGFR-sparing tyrosine kinase inhibitor, elicited durable responses and demonstrated clinical benefit in patients with advanced, previously treated...

The ASCO Post

May 23, 2025

NCCN Clinical Practice Guidelines in Oncology: 2025 Updates

The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are availa...

The ASCO Post

May 23, 2025

FDA Approves Doublet for KRAS-Mutated, Recurrent, Low-Grade Serous Ovarian Cancer

Today, the FDA granted accelerated approval to the combination of the dual RAF/MEK inhibitor avutometinib and the FAK inhibitor defactinib (Avmapki Fakzynja Co-pack) for adults with KRAS-mutated, recu...

The ASCO Post

May 23, 2025

Association for Clinical Oncology: Proposed Changes to Federal Health Agencies Threaten Future Cancer Research Advancements

The Association for Clinical Oncology is carefully reviewing the Administration’s Fiscal Year 2026 (FY 2026) budget proposal, which was released on May 2 and contains significant cuts to federal healt...

The ASCO Post

May 23, 2025

Bringing Evidence-Based Integrative Medicine Into Everyday Oncology Practice

Despite the significant rise over the past 50 years in the use of evidence-based integrative medicine in conjunction with conventional cancer treatments—up from just 20% in the 1970s to about 80% in 2...

The ASCO Post

May 23, 2025

Together, We’re Building a Better Future for People With Cancer and for Our Profession

For more than 25 years, my goal as a community oncologist has been to ensure that all patients have access to the highest-quality cancer care. This is the future I stood for when I became ASCO’s 61st ...

The ASCO Post

May 23, 2025

Early-Stage Nonrectal Mismatch Repair–Deficient Tumors Respond to Neoadjuvant PD-1 Blockade, Facilitating Nonoperative Management

Mismatch repair–deficient (dMMR) tumors beyond those in the rectum may respond to PD-1 blockade in the neoadjuvant setting, offering the option of organ preservation in early-stage cancer regardless o...

The ASCO Post

May 23, 2025

The Legal Impacts on Oncology Care of Prohibiting Diversity, Equity, and Inclusion Efforts

In January 2025, the Trump Administration issued executive orders asserting opposition to diversity, equity, and inclusion (DEI) programs on the federal level and rescinding Biden Administration order...

The ASCO Post